Resistance of endothelial cells to SARS-CoV-2 infection in vitro
Author:
Ahmetaj-Shala BlerinaORCID, Peacock Thomas P.ORCID, Baillon LauryORCID, Swann Olivia C.ORCID, Gashaw Hime, Barclay Wendy S.ORCID, Mitchell Jane A.
Abstract
AbstractRationaleThe secondary thrombotic/vascular clinical syndrome of COVID-19 suggests that SARS-CoV-2 infects not only respiratory epithelium but also the endothelium activating thrombotic pathways, disrupting barrier function and allowing access of the virus to other organs of the body. However, a direct test of susceptibility to SARS-CoV-2 of authentic endothelial cell lines has not been performed.ObjectiveTo determine infectibility of primary endothelial cell lines with live SARS-CoV-2 and pseudoviruses expressing SARS-CoV-2 spike protein.Methods and ResultsExpression of ACE2 and BSG pathways genes was determined in three types of endothelial cells; blood outgrowth, lung microvascular and aortic endothelial cells. For comparison nasal epithelial cells, Vero E6 cells (primate kidney fibroblast cell line) and HEK 293T cells (human embryonic kidney cells) transfected with either ACE2 or BSG were used as controls. Endothelial and Vero E6 cells were treated with live SARS-CoV-2 virus for 1 hour and imaged at 24 and 72 hours post infection. Pseudoviruses containing SARS-CoV-2, Ebola and Vesicular Stomatis Virus glycoproteins were generated and added to endothelial cells and HEK 239Ts for 2 hours and infection measured using luminescence at 48 hours post infection. Compared to nasal epithelial cells, endothelial cells expressed low or undetectable levels of ACE2 and TMPRSS2 but comparable levels of BSG, PPIA and PPIB. Endothelial cells showed no susceptibility to live SARS-CoV-2 or SARS-CoV-2 pseudovirus (but showed susceptibility to Ebola and Vesicular Stomatitis Virus). Overexpression of ACE2 but not BSG in HEK 239T cells conferred SARS-CoV-2 pseudovirus entry. Endothelial cells primed with IL-1ß remained resistant to SARS-CoV-2.ConclusionEndothelial cells are resistant to infection with SARS-CoV-2 virus, in line with relatively low levels of ACE2 and TMPRSS2, suggesting that the vascular dysfunction and thrombosis seen in severe COVID-19 is a result of factors released by adjacent infected cells (e.g. epithelial cells) and/or circulating, systemic inflammatory mediators.
Publisher
Cold Spring Harbor Laboratory
Reference21 articles.
1. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. 2. Angiotensin‐converting enzyme 2 (
ACE2
),
SARS‐CoV
‐2 and the pathophysiology of coronavirus disease 2019 (
COVID
‐19) 3. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor 4. Ulrich H and Pillat MM . CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement. Stem Cell Rev Rep. 2020. 5. Wang, K , Chen, W , Zhou, YS , Lian, JQ , Zhang, Z , Du, P , Gong, L , Zhang, Y , Cui, HY , Geng, JJ , Wang, B , Sun, XX , Wang, CF , Yang, X , Lin, P , Deng, YQ , Wei, D , Yang, XM , Zhu, YM , Zhang, K , Zheng, ZH , Miao, JL , Guo, T , Shi, Y , Zhang, S , Fu, L , Wang, QY , Bian, H , Zhu P and Chen ZN . SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. BioRxiv preprint 2020.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|